GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (FRA:RGN) » Definitions » Cyclically Adjusted Price-to-FCF

Repligen (FRA:RGN) Cyclically Adjusted Price-to-FCF : 196.23 (As of Jun. 03, 2024)


View and export this data going back to . Start your Free Trial

What is Repligen Cyclically Adjusted Price-to-FCF?

As of today (2024-06-03), Repligen's current share price is €135.40. Repligen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.69. Repligen's Cyclically Adjusted Price-to-FCF for today is 196.23.

The historical rank and industry rank for Repligen's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

FRA:RGN' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 44.35   Med: 210.29   Max: 621.65
Current: 201.68

During the past years, Repligen's highest Cyclically Adjusted Price-to-FCF was 621.65. The lowest was 44.35. And the median was 210.29.

FRA:RGN's Cyclically Adjusted Price-to-FCF is ranked worse than
94.09% of 237 companies
in the Medical Devices & Instruments industry
Industry Median: 43.21 vs FRA:RGN: 201.68

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Repligen's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €0.591. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €0.69 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Repligen Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Repligen's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Cyclically Adjusted Price-to-FCF Chart

Repligen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 237.43 415.67 466.39 271.70 260.10

Repligen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 270.20 220.39 231.90 260.10 248.78

Competitive Comparison of Repligen's Cyclically Adjusted Price-to-FCF

For the Medical Instruments & Supplies subindustry, Repligen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Repligen's Cyclically Adjusted Price-to-FCF falls into.



Repligen Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Repligen's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=135.40/0.69
=196.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repligen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Repligen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.591/131.7762*131.7762
=0.591

Current CPI (Mar. 2024) = 131.7762.

Repligen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.038 100.560 0.050
201409 0.107 100.428 0.140
201412 -0.021 99.070 -0.028
201503 -0.099 99.621 -0.131
201506 0.184 100.684 0.241
201509 0.166 100.392 0.218
201512 0.076 99.792 0.100
201603 -0.114 100.470 -0.150
201606 0.250 101.688 0.324
201609 -0.084 101.861 -0.109
201612 0.030 101.863 0.039
201703 -0.004 102.862 -0.005
201706 0.036 103.349 0.046
201709 -0.054 104.136 -0.068
201712 0.256 104.011 0.324
201803 0.000 105.290 0.000
201806 0.059 106.317 0.073
201809 0.290 106.507 0.359
201812 0.002 105.998 0.002
201903 0.114 107.251 0.140
201906 0.225 108.070 0.274
201909 0.264 108.329 0.321
201912 0.179 108.420 0.218
202003 0.077 108.902 0.093
202006 0.204 108.767 0.247
202009 0.260 109.815 0.312
202012 0.047 109.897 0.056
202103 0.003 111.754 0.004
202106 0.299 114.631 0.344
202109 0.161 115.734 0.183
202112 0.249 117.630 0.279
202203 -0.079 121.301 -0.086
202206 0.325 125.017 0.343
202209 -0.284 125.227 -0.299
202212 0.670 125.222 0.705
202303 0.028 127.348 0.029
202306 0.407 128.729 0.417
202309 0.497 129.860 0.504
202312 0.295 129.419 0.300
202403 0.591 131.776 0.591

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Repligen  (FRA:RGN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Repligen Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Repligen's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen (FRA:RGN) Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.

Repligen (FRA:RGN) Headlines

No Headlines